Article
Biochemistry & Molecular Biology
Alberto Lozano-Ros, Maria L. Martinez-Gines, Jose M. Garcia-Dominguez, Sara Salvador-Martin, Haydee Goicochea-Briceno, Juan P. Cuello, Ariana Meldana-Rivera, Yolanda Higueras-Hernandez, Maria Sanjurjo-Saez, Luis A. Alvarez-Sala-Walther, Luis A. Lopez-Fernandez
Summary: Vitamin D plays a significant role in regulating multiple sclerosis. This study analyzed the regulatory effect of vitamin D on the TGF-beta signaling pathway in patients with relapsing-remitting multiple sclerosis. The results showed that the regulation of TGF-beta pathway genes by vitamin D is indirect.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Sandra D. Cassard, Kathryn C. Fitzgerald, Peiqing Qian, Susan A. Emrich, Christina J. Azevedo, Andrew D. Goodman, Elizabeth A. Sugar, Daniel Pelletier, Emmanuelle Waubant, Ellen M. Mowry
Summary: The VIDAMS trial aimed to determine if high dose versus low dose vitamin D3 supplementation reduces the risk of clinical relapse in MS patients. The study found that high dose vitamin D3 supplementation did not reduce the risk of relapse in RRMS patients, suggesting that prescribing higher doses of vitamin D may not be beneficial for modifying the course of RRMS.
Article
Immunology
Emanuele D'Amico, Aurora Zanghi, Nunziatina Laura Parrinello, Alessandra Romano, Giuseppe Alberto Palumbo, Clara Grazia Chisari, Simona Toscano, Francesco Di Raimondo, Mario Zappia, Francesco Patti
Summary: This study characterized the immune cell phenotypes of patients recently diagnosed with relapsing-remitting multiple sclerosis who had not received disease-modifying therapies. The results revealed differences in myeloid, B, and T cells between these patients and healthy controls.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Clinical Neurology
Seraj Makkawi, Ammar Aljabri, Ghassan Bin Lajdam, Ammar Albakistani, Abdulrahman Aljohani, Suhail Labban, Razaz Felemban
Summary: This study identified the relationship between seasonal variation and relapse rate in RRMS patients in Jeddah, Saudi Arabia, and found that the relapse rate was higher during the winter and correlated with low vitamin D levels. However, relapses are likely multifactorial, and more population-based studies are needed to understand the role of environmental variables in MS exacerbation.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Pablo Rodriguez de Vera Gomez, Mariola Mendez Muros, Alberto Torres Cuadro, Francisco Javier Toyos Saenz de Miera, Rocio Lopez Ruiz, Raquel Guerrero Vazquez, Juan Jesus Garcia Gonzalez, Antonio Manuel Garrido Hermosilla, Tomas Martin Hernandez
Summary: This study describes the clinical and biochemical characteristics of GD-ALZ and the clinical course of GO-ALZ cases in patients treated with Alemtuzumab for RRMS. GD-ALZ was observed in 32.6% of the cases, mainly affecting women with an average age of 41.9 years. Having first-degree relatives with hypothyroidism was identified as a risk factor. GO-ALZ was diagnosed in 13.6% of the cases, with 3 cases requiring anti-IL-6 treatment.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Zhizheng Zhuo, Yongmei Li, Yunyun Duan, Guanmei Cao, Fenglian Zheng, Jinli Ding, Decai Tian, Xinli Wang, Jinhui Wang, Xinghu Zhang, Kuncheng Li, Fuqing Zhou, Muhua Huang, Yuxin Li, Haiqing Li, Chun Zeng, Ningnannan Zhang, Jie Sun, Chunshui Yu, Xuemei Han, Sven Haller, Frederik Barkhof, Fudong Shi, Yaou Liu
Summary: Three MRI subtypes of RRMS were identified with distinct clinical and imaging features and different prognoses. The subtypes showed variations in cognitive impairment and conversion rate to SPMS.
JOURNAL OF NEUROLOGY
(2021)
Article
Multidisciplinary Sciences
Insha Zahoor, Hamid Suhail, Indrani Datta, Mohammad Ejaz Ahmed, Laila M. Poisson, Jeffrey Waters, Faraz Rashid, Rui Bin, Jaspreet Singh, Mirela Cerghet, Ashok Kumar, Md Nasrul Hoda, Ramandeep Rattan, Ashutosh K. Mangalam, Shailendra Giri
Summary: Metabolic aberrations were found to impact the pathogenesis of relapsing-remitting multiple sclerosis, with changes in multiple metabolic pathways identified in patient samples. Enhanced glycolysis in immune cells of MS patients was observed, and treatment with a glycolytic inhibitor showed promising effects in ameliorating disease progression by promoting an antiinflammatory phenotype. This study highlights the potential of blood-based metabolomic approaches in identifying therapeutic targets for developing new treatment strategies for multiple sclerosis.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Immunology
Tatiana Koudriavtseva, Svetlana Lorenzano, Maria Cellerino, Mauro Truglio, Marco Fiorelli, Caterina Lapucci, Giovanna D'Agosto, Laura Conti, Annunziata Stefanile, Silvana Zannino, Maria Maddalena Filippi, Antonio Cortese, Carlo Piantadosi, Marta Maschio, Andrea Maialetti, Edvina Galie, Marco Salvetti, Matilde Inglese
Summary: The objective of this observational study was to identify the most specific pro-coagulative/vascular factors for multiple sclerosis pathogenesis and to correlate them with brain hemodynamic abnormalities. The results showed that tissue-factor was one of the key variables in differentiating multiple sclerosis from controls and relapse from remission.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Cell Biology
Carsten Carlberg, Marcin P. Mycko
Summary: Environmental factors, such as low vitamin D levels, contribute to the susceptibility of multiple sclerosis (MS), an autoimmune disease affecting the central nervous system. Vitamin D3, through its metabolite 1,25(OH)2D3, modulates the epigenome and transcriptome of immune cells, reducing inflammatory reactions and promoting immunological tolerance in T cells, thus preventing MS.
Article
Clinical Neurology
Rita Rodrigues, Raquel Rocha, Goncalo Bonifacio, Daniela Ferro, Francisco Sabenca, Ana Isabel Goncalves, Filipe Correia, Joaquim Pinheiro, Jose Leal Loureiro, Rui Pedro Guerreiro, Jose Vale, Maria Jose Sa, Andreia Costa
Summary: Therapeutic inertia (TI) is a common issue in the management of RRMS patients in Portugal, with approximately 1 in 5 patients exhibiting TI. Factors such as absence of relapses, current use of disease-modifying therapies (DMT), absence of adverse events, and care level of the treatment center are associated with TI. Further studies are needed to explore the impact of these factors on therapeutic decisions in RRMS patients.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Article
Clinical Neurology
Malin Boremalm, Peter Sundstrom, Jonatan Salzer
Summary: Rituximab is safe and effective in treating RRMS, with long-term effects on inflammatory disease activity. Disease reactivation is rare in MS patients who discontinued treatment, and low-dose rituximab (< 1000 mg yearly) is sufficient to maintain suppression of inflammatory disease activity in stable patients.
JOURNAL OF NEUROLOGY
(2021)
Article
Immunology
Nicole Kashani, Eve E. Kelland, Borna Vajdi, Lauren M. Anderson, Wendy Gilmore, Brett T. Lund
Summary: This study revealed that patients treated with alemtuzumab for multiple sclerosis showed an increase in the number and function of regulatory B cells after treatment, which were positively correlated with regulatory T cells. Additionally, an anti-inflammatory bias in monocytes was observed after the second annual course of treatment. These findings highlight the importance of further studies on all regulatory cell types following alemtuzumab treatment to understand the mechanisms of drug action and identify key predictors of durable clinical efficacy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Clinical Neurology
Johannes Lorscheider, Pascal Benkert, Carmen Lienert, Peter Haenni, Tobias Derfuss, Jens Kuhle, Ludwig Kappos, Oezguer Yaldizli
Summary: In a real-world setting, dimethyl fumarate and fingolimod demonstrate comparable effectiveness in reducing relapses and disability worsening in patients with RRMS. Findings from this study suggest that there is no significant difference in efficacy between the two treatment options, regardless of whether patients are treatment-naive or switching from another DMT.
JOURNAL OF NEUROLOGY
(2021)
Article
Clinical Neurology
Malthe Faurschou Wandall-Holm, Mathias Due Buron, Tine Iskov Kopp, Karsten Thielen, Finn Sellebjerg, Melinda Magyari
Summary: Initiating treatment early reduces the risk of disability pension in patients with RRMS. This finding highlights the importance of early diagnosis and treatment on a patient-centered, socioeconomic disability milestone.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Review
Biochemistry & Molecular Biology
Sylwia Pietrasik, Angela Dziedzic, Elzbieta Miller, Michal Starosta, Joanna Saluk-Bijak
Summary: Multiple sclerosis is a neurodegenerative disease with a variable course, often characterized by alternating periods of exacerbation and stabilization. Distinguishing between subtypes early can lead to faster implementation of appropriate treatment. Research suggests circulating microRNAs may be valuable for MS diagnosis and predicting disease subtype.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Neuroimaging
Sindhuja Tirumalai Govindarajan, Yilin Liu, Maria Andrea Parra Corral, Lev Bangiyev, Lauren Krupp, Leigh Charvet, Tim Q. Duong
Summary: Slowed information processing speed is an early marker of cognitive impairment in multiple sclerosis and is associated with white matter integrity. Identifying white matter tracts related to processing speed in pediatric and young age onset MS can aid in early therapeutic intervention.
BRAIN IMAGING AND BEHAVIOR
(2021)
Review
Clinical Neurology
Angelo Ghezzi, Brenda Banwell, Amit Bar-Or, Tanuja Chitnis, Russell C. Dale, Mark Gorman, Barbara Kornek, Lauren Krupp, Kristen M. Krysko, Margherita Nosadini, Kevin Rostasy, Jonatan Salzer, Teri Schreiner, Silvia Tenembaum, Emmanuelle Waubant
Summary: This paper discusses the use of rituximab in pediatric multiple sclerosis and other inflammatory immune-mediated disorders of the central nervous system, aiming to establish a protocol for its clinical practice, including dosage, administration interval, treatment duration, and necessary tests for baseline and follow-up evaluations.
MULTIPLE SCLEROSIS JOURNAL
(2021)
Article
Clinical Neurology
Tanuja Chitnis, Brenda Banwell, Lauren Krupp, Douglas L. Arnold, Amit Bar-Or, Wolfgang Brueck, Gavin Giovannoni, Benjamin Greenberg, Angelo Ghezzi, Emmanuelle Waubant, Kevin Rostasy, Kumaran Deiva, Peter Huppke, Jerry S. Wolinsky, Ying Zhang, Amin Azmon, Annik K-Laflamme, Rajesh Karan, Jutta Gaertner
Summary: Treatment with fingolimod rapidly reduces absolute lymphocyte count (ALC) in pediatric-onset multiple sclerosis (POMS), but infection rates are comparable to intramuscular interferon beta-1a. No association was observed between nadir ALC and infections.
MULTIPLE SCLEROSIS JOURNAL
(2021)
Article
Neurosciences
Sindhuja T. Govindarajan, Ruiqi Pan, Lauren Krupp, Leigh Charvet, Tim Q. Duong
Summary: The study reveals that slowed processing on different components of attention in multiple sclerosis patients is associated with specific gray matter changes in the brain. Even in young patients with mild disease severity, ANT-I scores and cortical thickness were not significantly different, but thalamic volumes were lower in MS. Associations between attentional performance and gray matter changes were observed, suggesting a relationship between brain structure and cognitive function in MS patients.
Article
Clinical Neurology
Tehila Eilam-Stock, Pamela Best, Kathleen Sherman, Michael T. Shaw, Joseph Ventura, Lauren B. Krupp, Leigh E. Charvet
Summary: The study utilized the Cognitive Assessment Interview (CAI) to assess individuals with MS, finding that processing speed, working memory, and learning and memory problems were most commonly reported. CAI ratings showed moderate correlation with self-report measures, but only mild correlation with objective neuropsychological measures specific to executive functions.
FRONTIERS IN NEUROLOGY
(2021)
Article
Clinical Neurology
Giuseppina Pilloni, Martin Malik, Raghav Malik, Lauren Krupp, Leigh Charvet
Summary: The computer-based protocol for grip assessment showed that pediatric-onset multiple sclerosis patients had higher dynamic and static fatigue indices compared to healthy controls, indicating potential motor involvement that may require intervention to prevent future disability.
JOURNAL OF CHILD NEUROLOGY
(2021)
Article
Clinical Neurology
Tehila Eilam-Stock, Michael T. Shaw, Lauren B. Krupp, Leigh E. Charvet
Summary: This study compared the sensitivity and specificity of different clinical, computer-based and experimental measures to early cognitive involvement in MS. It found that the computer-based Cogstate reaction time, ANT-I intra-individual variability, and TECA scores were the most sensitive and specific markers of cognitive involvement in MS.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2021)
Article
Pediatrics
Cristina Fernandez-Carbonell, Leigh E. Charvet, Lauren B. Krupp
Summary: Pediatric-onset multiple sclerosis, accounting for about 5% of all MS cases, primarily diagnosed in adolescence, requires holistic management for pediatric patients to optimize health and well-being. Strategies include disease-modifying therapies, high levels of vitamin D, exercise, and behavioral interventions to improve quality of life.
Article
Clinical Neurology
Prince Sebastian, Nicolas Cherbuin, Lisa F. Barcellos, Shelly Roalstad, Charles Casper, Janace Hart, Gregory S. Aaen, Lauren Krupp, Leslie Benson, Mark Gorman, Meghan Candee, Tanuja Chitnis, Manu Goyal, Benjamin Greenberg, Soe Mar, Moses Rodriguez, Jennifer Rubin, Teri Schreiner, Amy Waldman, Bianca Weinstock-Guttman, Jennifer Graves, Emmanuelle Waubant, Robyn Lucas
Summary: This study aims to determine the effects of sun exposure and ultraviolet radiation (UVR) exposure on the risk of pediatric-onset multiple sclerosis (MS). The results showed that spending more time outdoors during summer and higher summer ambient UVR dose were associated with a reduced risk of developing MS in children.
Article
Clinical Neurology
Lauren B. Krupp, Emmanuelle Waubant, Michael Waltz, T. Charles Casper, Anita Belman, Yolanda Wheeler, Jayne Ness, Jennifer Graves, Mark Gorman, Leslie Benson, Soe Mar, Manu Goyal, Teri Schreiner, Bianca Weinstock-Guttman, Moses Rodriguez, Jan-Mendelt Tillema, Timothy Lotze, Greg Aaen, Mary Rensel, John Rose, Tanuja Chitinis, Allan George, Leigh E. Charvet
Summary: The cognitive differences between pediatric and adult multiple sclerosis (MS) are not well understood. This study compared cognitive performances in pediatric MS, adult MS, and pediatric healthy controls, and found that pediatric MS patients perform better than adults with MS on cognitive screens.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Raffaella Pizzolato Umeton, Michael Waltz, Gregory S. Aaen, Leslie Benson, Mark Gorman, Manu Goyal, Jennifer S. Graves, Yolanda Harris, Lauren Krupp, Timothy E. Lotze, Nikita M. Shukla, Soe Mar, Jayne Ness, Mary Rensel, Teri Schreiner, Jan-Mendelt Tillema, Shelly Roalstad, Moses Rodriguez, John Rose, Emmanuelle Waubant, Bianca Weinstock-Guttman, Charles Casper, Tanuja Chitnis
Summary: This retrospective cohort study evaluated cases of children with NMOSD and found that the use of disease-modifying treatments, particularly rituximab, is associated with a lowered annualized relapse rate in children with NMOSD AQP4+.
Letter
Clinical Neurology
Erica Parrotta, Hannah Kopinsky, Jennifer Abate, Lana Zhovtis Ryerson, Lauren B. Krupp
Summary: B-cell depleting therapies such as rituximab and ocrelizumab, commonly used for Multiple Sclerosis treatment, have increased risks of adverse reactions, one of which is the rarely reported pyoderma gangrenosum (PG), an inflammatory, ulcerative skin disease. We describe two patients with Relapsing-Remitting Multiple Sclerosis who developed PG while on rituximab, and their diagnoses were supported by clinical symptoms, biopsy reports, and response to treatment.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Clinical Neurology
Teri Schreiner, Molly Wilson-Murphy, Jan Mendelt-Tillema, Michael Waltz, Rachel Codden, Leslie Benson, Mark Gorman, Manu Goyal, Lauren Krupp, Tim Lotze, Soe Mar, Jayne Ness, Mary Rensel, Shelly Roalstad, Moses Rodriguez, John Rose, Nikita Shukla, Emmanuelle Waubant, Yolanda Wheeler, T. Charles Casper, Tanuja Chitnis
Summary: This study found a higher prevalence of SARS-CoV-2 infection among pediatric patients with POMS and related disorders, with a higher risk of hospitalization and ICU admission for those receiving B-cell depleting therapy, suggesting a higher risk of severe infection in this population.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Lauren Krupp, Brenda Banwell, Tanuja Chitnis, Kumaran Deiva, Jutta Gaertner, Angelo Ghezzi, Peter Huppke, Emmanuelle Waubant, Virginia DeLasHeras, Amin Azmon, Rajesh Karan
Summary: Fingolimod improves health-related quality of life compared with IFN beta-1a in patients with paediatric-onset multiple sclerosis, as evidenced by self-reported and parent-reported PedsQL scores.
BMJ NEUROLOGY OPEN
(2022)
Article
Clinical Neurology
Tehila Eilam-Stock, Michael T. Shaw, Kathleen Sherman, Lauren B. Krupp, Leigh E. Charvet
Summary: The study showed a strong correlation between remote and in-person administration of the SDMT among 132 participants, confirming the reliability of remote administration as a cognitive screening approach in MS.
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL
(2021)